A Phase 2 interventional study of TP-434 and Ertapenem in Complicated Intra-abdominal Infection, sponsored by Tetraphase Pharmaceuticals, Inc.. Completed at 38 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-06.
Sponsored by Tetraphase Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 2, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of two dose regimens of TP-434 compared with ertapenem in the treatment of adult community-acquired complicated intra-abdominal infections (cIAIs).
129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.
This study's enrollment of 143 is close to the median of 140 across 77 interventional studies indexed under Intraabdominal Infections.
Browse Intraabdominal Infections studies →Tetraphase Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TP-434 was administered intravenously (IV) at a dose of 1.5 milligrams per kilogram of body weight (mg/kg) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
Drug: TP-434 · Drug: Placebo
TP-434 was administered IV at a dose of 1.0 mg/kg every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
Drug: TP-434 · Drug: Placebo
Ertapenem was administered IV at a dose of 1 gram (g) q24h for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
Drug: Ertapenem · Drug: Placebo
Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Test-of-Cure Visit
Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (Test-of-Cure \[TOC\] assessment was not available, death unrelated to cIAI, or some other reason).
Time frame: TOC Visit (10-14 days after last dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at the End-of-Treatment (EOT) Visit
Time frame: EOT Visit (4-14 days after first dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at TOC Visit
Time frame: TOC Visit (10-14 days after last dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Modified Intent-to-treat (MITT) Population at the Follow-up Visit
Time frame: Follow-up Visit (28-42 days after last dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the EOT Visit
Time frame: EOT Visit (4-14 days after first dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the TOC Visit
Time frame: TOC Visit (10-14 days after last dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Clinically Modified Intent-to-treat (c-MITT) Population at the Follow-up Visit
Time frame: Follow-up Visit (28-42 days after last dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the EOT Visit
Time frame: EOT Visit (4-14 days after first dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the TOC Visit
Time frame: TOC Visit (10-14 days after last dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Microbiologically Modified Intent-to-treat (m-MITT) Population at the Follow-up Visit
Time frame: Follow-Up Visit (28-42 days after last dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the EOT Visit
Time frame: EOT Visit (4-14 days after first dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the TOC Visit
Time frame: TOC Visit (10-14 days after last dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Clinically Evaluable (CE) Population at the Follow-up Visit
Time frame: Follow-up Visit (28-42 days after last dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the EOT Visit
Time frame: EOT Visit (4-14 days after first dose of study drug)
Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Follow-up Visit
Time frame: Follow-up Visit (28-42 days after last dose of study drug)
Microbiologic Response to TP-434 and Ertapenem in the m-MITT Population at the EOT Visit
Microbiological response was classified as favorable (eradication or presumed eradication), unfavorable (persistence, presumed persistence, superinfection, or new infection), or indeterminate (assessment not possible).
Time frame: EOT Visit (4-14 days after first dose of study drug)
Microbiologic Response to TP-434 and Ertapenem in the m-MITT Population at the TOC Visit
Time frame: TOC Visit (10-14 days after last dose of study drug)
Microbiologic Response to TP-434 and Ertapenem in the ME Population at the EOT Visit
Time frame: EOT Visit (4-14 days after first dose of study drug)
Microbiologic Response to TP-434 and Ertapenem in the ME Population at the TOC Visit
Time frame: TOC Visit (10-14 days after last dose of study drug)
Pharmacokinetics: Maximum Concentration (Cmax) of TP-434
Time frame: Prior to first infusion and 1, 3, 7, 12, 48, and 108 hours after start of first infusion
Pharmacokinetics: Area Under the Concentration Time Curve From Time 0 to 12 Hours (AUC[0-12]) of TP-434
Time frame: Prior to first infusion and 1, 3, 7, 12, 48, and 108 hours after start of first infusion
| Milestone | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem, 1 g q24h |
|---|---|---|---|
| Started | 56 | 57 | 30 |
| Received at least 1 dose of study drug | 54 | 56 | 29 |
| Completed | 44 | 49 | 26 |
| Not completed | 12 | 8 | 4 |
| Withdrew: Lost to follow-up | 5 | 3 | 2 |
| Withdrew: Withdrawal by subject | 0 | 5 | 0 |
| Withdrew: Physician decision | 1 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Death | 3 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 |
| Withdrew: Incorrectly randomized | 0 | 0 | 1 |
Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (Test-of-Cure \[TOC\] assessment was not available, death unrelated to cIAI, or some other reason).
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 39 | 41 | 24 |
| Failure | 3 | 0 | 2 |
| Indeterminate | 0 | 0 | 0 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 49 | 52 | 28 |
| Failure | 2 | 1 | 1 |
| Indeterminate | 3 | 3 | 0 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 46 | 47 | 26 |
| Failure | 3 | 1 | 2 |
| Indeterminate | 5 | 8 | 1 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 41 | 45 | 24 |
| Failure | 4 | 1 | 2 |
| Indeterminate | 9 | 10 | 3 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 49 | 52 | 28 |
| Failure | 2 | 1 | 1 |
| Indeterminate | 3 | 3 | 0 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 46 | 47 | 26 |
| Failure | 3 | 1 | 2 |
| Indeterminate | 5 | 8 | 1 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 41 | 45 | 24 |
| Failure | 4 | 1 | 2 |
| Indeterminate | 9 | 10 | 3 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 41 | 44 | 26 |
| Failure | 2 | 0 | 1 |
| Indeterminate | 2 | 3 | 0 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 39 | 41 | 24 |
| Failure | 3 | 0 | 2 |
| Indeterminate | 3 | 6 | 1 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 36 | 39 | 22 |
| Failure | 4 | 0 | 2 |
| Indeterminate | 5 | 8 | 3 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 47 | 47 | 27 |
| Failure | 2 | 1 | 1 |
| Indeterminate | 0 | 0 | 0 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 46 | 47 | 26 |
| Failure | 3 | 1 | 2 |
| Indeterminate | 0 | 0 | 0 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 41 | 45 | 23 |
| Failure | 4 | 1 | 2 |
| Indeterminate | 4 | 2 | 3 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 40 | 41 | 25 |
| Failure | 2 | 0 | 1 |
| Indeterminate | 0 | 0 | 0 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Cure | 36 | 39 | 21 |
| Failure | 4 | 0 | 2 |
| Indeterminate | 2 | 2 | 3 |
Microbiological response was classified as favorable (eradication or presumed eradication), unfavorable (persistence, presumed persistence, superinfection, or new infection), or indeterminate (assessment not possible).
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Favorable | 41 | 44 | 26 |
| Unfavorable | 2 | 0 | 1 |
| Indeterminate | 2 | 3 | 0 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Favorable | 39 | 42 | 24 |
| Unfavorable | 3 | 0 | 2 |
| Indeterminate | 3 | 5 | 1 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Favorable | 40 | 41 | 25 |
| Unfavorable | 2 | 0 | 1 |
| Indeterminate | 0 | 0 | 0 |
| participants | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Favorable | 39 | 41 | 24 |
| Unfavorable | 3 | 0 | 2 |
| Indeterminate | 0 | 0 | 0 |
| nanograms per milliliter (ng/mL) | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h |
|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of TP-434 | 1445.625 ± 1168.029 | 952.608 ± 759.754 |
| nanogram*hours per milliliter (ng*h/mL) | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h |
|---|---|---|
| Pharmacokinetics: Area Under the Concentration Time Curve From Time 0 to 12 Hours (AUC[0-12]) of TP-434 | 4349.900 ± 2186.791 | 3240.724 ± 1732.172 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TP-434, 1.5 mg/kg q24h | — | 6/53 (11.3%) | 11/53 (20.8%) |
| TP-434, 1.0 mg/kg q12h | — | 1/56 (1.8%) | 10/56 (17.9%) |
| Ertapenem 1 g q24h | — | 1/30 (3.3%) | 7/30 (23.3%) |
| Event | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| Subdiaphragmatic AbscessInfections and infestations | 0/53 | 0/56 | 1/30 |
| Lobar PneumoniaInfections and infestations | 1/53 | 0/56 | 0/30 |
| Duodenal Ulcer HaemorrhageGastrointestinal disorders | 1/53 | 0/56 | 0/30 |
| Abdominal Wall AbscessInfections and infestations | 1/53 | 0/56 | 0/30 |
| Atrial FibrillationCardiac disorders | 1/53 | 0/56 | 0/30 |
| EmbolismVascular disorders | 1/53 | 0/56 | 0/30 |
| IleusGastrointestinal disorders | 1/53 | 0/56 | 0/30 |
| Wound InfectionInfections and infestations | 0/53 | 1/56 | 0/30 |
| Event | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/53 | 6/56 | 2/30 |
| Lipase IncreasedInvestigations | 3/53 | 4/56 | 2/30 |
| VomitingGastrointestinal disorders | 3/53 | 1/56 | 0/30 |
| Blood Amylase IncreasedInvestigations | 3/53 | 2/56 | 1/30 |
| Abdominal PainGastrointestinal disorders | 2/53 | 0/56 | 0/30 |
| ThrombophlebitisVascular disorders | 1/53 | 2/56 | 0/30 |
| Application Site HypersensitivityGeneral disorders | 0/53 | 0/56 | 1/30 |
| PyrexiaGeneral disorders | 1/53 | 1/56 | 1/30 |
| HypersensitivityImmune system disorders | 0/53 | 0/56 | 1/30 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 1/53 | 0/56 | 1/30 |
All randomized participants.
| Age, Continuous(years) | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h | Total |
|---|---|---|---|---|
| Mean | 43.6 ± 18.39 | 42.1 ± 17.16 | 41.8 ± 17.60 | 42.6 ± 17.64 |
| Sex: Female, Male(Participants) | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h | Total |
|---|---|---|---|---|
| Female | 18 | 14 | 8 | 40 |
| Male | 38 | 43 | 22 | 103 |
| Region of Enrollment(participants) | TP-434, 1.5 mg/kg q24h | TP-434, 1.0 mg/kg q12h | Ertapenem 1 g q24h | Total |
|---|---|---|---|---|
| United States | 0 | 0 | 1 | 1 |
| Romania | 6 | 9 | 6 | 21 |
| Lithuania | 17 | 13 | 7 | 37 |
| Bulgaria | 9 | 6 | 3 | 18 |
| Latvia | 8 | 9 | 4 | 21 |
| India | 16 | 20 | 9 | 45 |
The record gives a start of Jan 2011, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eravacycline
Tetraphase Pharmaceuticals, Inc.